Preferred Label : CDK4 Inhibitor BGB-43395;
NCIt definition : An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), with potential
antineoplastic activity. Upon oral administration, CDK4 inhibitor BGB-43395 selectively
inhibits CDK4, which inhibits the phosphorylation of retinoblastoma protein (Rb) early
in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle
arrest. This suppresses DNA replication and inhibits tumor cell proliferation. CDK4,
a serine/threonine kinase, is upregulated in many tumor cell types and plays a key
role in the regulation of both cell cycle progression from the G1-phase into the S-phase
and tumor cell proliferation.;
Molecule name : BGB 43395; BGB-43395;
NCI Metathesaurus CUI : CL1922478;
Origin ID : C203660;
UMLS CUI : C5908016;
Semantic type(s)
- concept_is_in_subset
- has_target
